If you have been reading about preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-30. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
=== From vitamers === Animals are auxotroph for this enzyme co-factor and require it or an intermediate to be supplemented, hence its classification as a vitamin, unlike MoCo or CoQ10 for example. PLP is synthesized from pyridoxal by the enzyme pyridoxal kinase (gene PDXK), requiring one ATP molecule. PDXK can also produce 5'-phosphates of the other vitamers (pyridoxine and pyridoxamine), with pyridoxine 5′-phosphate oxidase converting these alternative 5'-phosphates into PLP. PLP is made and metabolized in the liver. PLP and other vitamin B6 phosphates can be broken down by pyridoxal phosphatase, which removes the phosphate group.
== Early life == On August 13, 1930, Walter David and Addie Turner Mizell welcomed their son Wilmer David into the world. Contrary to popular belief (caused by his nickname), Wilmer was actually born and raised in Leakesville, Mississippi, though the town of Vinegar Bend, Alabama was only a few miles away. His father died when he was two, and his grandmother and uncle brought him up, as his mother was sickly. He grew up laboring on the family farm, which produced fruit and vegetables. The Mizells also raised hogs and cattle. Additional income for Wilmer came from hauling wood, logging, and tapping turpentine from pine trees. "I walked behind more mules than I walked batters – and that's saying a lot," he later reflected, comparing his childhood with his career. Growing up, Mizell was unable to play catch with his brother because he was such an erratic thrower. He practiced his control by throwing at a smokehouse knothole, eventually knocking the door in because of all his practice. At the age of 16, he started playing for baseball teams, pitching in Sunday leagues around Vinegar Bend. The St. Louis Cardinals held a tryout camp in Biloxi, Mississippi, in 1948, and Mizell recorded three strikeouts before a thunderstorm ended it early. Impressed with the youngster, scout Buddy Lewis visited him the following year in Lakeville. Mizell, returning from a local swimming spot, impressed Lewis again with his fastball, and the scout promised to sign him for $500 upon his graduation from Leakeville High School, which would occur later that evening.
== Etymology == The name Malaysia is a combination of the word Malays and the Latin-Greek suffix -ia/-ία, which can be translated as 'land of the Malays'. Similar-sounding variants have also appeared in accounts older than the 11th century, as toponyms for areas in Sumatra or referring to a larger region around the Strait of Malacca. The Sanskrit text Vayu Purana, thought to have been in existence since the first millennium CE, mentioned a land named 'Malayadvipa', which was identified by certain scholars as the modern Malay Peninsula. Other notable accounts are by Ptolemy's 2nd-century Geographia, which used the name Malayu Kulon for the west coast of Golden Chersonese, and the 7th-century Yijing's account of Malayu. At some point, the Melayu Kingdom took its name from the Sungai Melayu. Melayu then became associated with Srivijaya, and remained associated with various parts of Sumatra, especially Palembang, where the founder of the Malacca Sultanate is thought to have come from. It is only thought to have developed into an ethnonym as Malacca became a regional power in the 15th century. Islamisation established an ethnoreligious identity in Malacca, with the term Melayu beginning to appear as interchangeable with Melakans. It may have specifically referred to local Malay speakers who were loyal to the Malaccan Sultan. The initial Portuguese use of Malayos reflected this, referring only to the ruling people of Malacca.
== Structure and contrast with other lipids == The 2,3-sn-glycerol structure and ether bond linkage are two key differences between lipids found in archaea vs those of bacteria and eukarya. The latter use 1,2-sn-glycerol, and mostly, ester bonds. Natural archaeol has 3R, 7R, 11R configurations for the three chiral centers in the isoprenoid chains. There are four structural variations, contributing to the complexity of the membrane lipids in function and properties. The two phytanyl chains can form a 36-member ring to yield macrocyclic archaeol. Hydroxylated archaeol has phytanyl chains hydroxylated at the first tertiary carbon atom, while sesterterpanyl archaeol have the phytanyl side chains with C25 sesterterpanyl chains, substituting at C2 of glycerol or at both carbons. Unsaturated archaeol, with the same carbon skeleton as standard archaeol but one or multiple double bonds in the phytanyl side chains is also discovered.
circular DNA Any DNA molecule, single-stranded or double-stranded, which forms a continuous closed loop without ends; e.g. bacterial chromosomes, mitochondrial and plastid DNA, as well as many other varieties of extrachromosomal DNA, including plasmids and some viral DNA. Contrast linear DNA.
Sources: en.wikipedia.org
PARPs have been shown to affect transcription factor structure and cause recruitment of many transcription factors to form complexes at DNA and elicit transcription. Mono(ADP-ribosyl)transferases are also shown to affect transcription factor binding at promoters. For example, PARP14, a mono (ADP-ribosyl)transferase, has been shown to affect STAT transcription factor binding. Other (ADP-ribosyl)transferases have been shown to modify proteins that bind mRNA, which can cause silencing of that gene transcript.
== Biological properties == According to a 2014 study, erythritol functions as an insecticide toxic to the fruit fly Drosophila melanogaster, impairing motor ability and reducing longevity even when nutritive sugars were available. Erythritol is preferentially used by the Brucella spp. The presence of erythritol in the placentas of goats, cattle, and pigs has been proposed as an explanation for the accumulation of Brucella bacteria found at these sites.
== Trials == Howard Florey's team at Oxford showed that Penicillium extract killed many kinds of bacteria. Gardner and Orr-Ewing tested it against gonococcus (against which it was most effective), meningococcus, streptococcus, staphylococcus, Bacillus anthracis, actinomyces and tetanus bacterium (Clostridium tetani) and the bacteria that cause gangrene. They observed bacteria attempting to grow in the presence of penicillin, and noted that penicillin was neither an enzyme that broke the bacteria down, nor an antiseptic that killed them; rather, it was a chemical that interfered with the process of cell division. Jennings observed that it had no effect on white blood cells, and would therefore reinforce rather than hinder the body's natural defences against bacteria. She also found that unlike sulphonamides, the first and only effective broad-spectrum antibiotic available at the time, it was not destroyed by pus. Medawar found that it did not affect the growth of tissue cells.
In 2007, US Fleet Tracking provided live GPS tracking to Gameday Management Group for use at the Super Bowl, tracking AFC and NFC Team buses, media buses, press buses, halftime entertainers, team owners and team family limousines, and other critical assets. US Fleet Tracking continues to provide these services for the Super Bowl each year, as it has each year since 2007 (through 2020). In 2013, US Fleet Tracking sponsored the FLS Microjet for its appearance at the EAA AirVenture Oshkosh airshow in Oshkosh, Wisconsin. The company demonstrated its live tracking technology at the event by installing its proprietary GPS equipment on the FLS Microjet and allowing the public to follow the course of the aircraft via a website in real time during the exhibition.
Sources: en.wikipedia.org
Édouard Manet's first major painting The Absinthe Drinker was controversial, and was rejected by the Paris Salon in 1859. Despite adopting sweeping EU food and beverage regulations in 1988 that effectively re-legalised absinthe, a decree was passed that same year that preserved the prohibition on products explicitly labelled as "absinthe", while placing strict limits on fenchone (fennel) and pinocamphone (hyssop) in an obvious, but failed, attempt to thwart a possible return of absinthe-like products. French producers circumvented this regulatory obstacle by labelling absinthe as spiritueux à base de plantes d'absinthe ('wormwood-based spirits'), with many either reducing or omitting fennel and hyssop altogether from their products. A legal challenge to the scientific basis of this decree resulted in its repeal (2009), which opened the door for the official French re-legalisation of absinthe for the first time since 1915. The French Senate voted to repeal the prohibition in mid-April 2011.
== Early career == After graduating from MIT, Swanson took a job at Citibank, where he managed a venture investment group. His performance pleased his supervisors, and he and a colleague were chosen to open a San Francisco office for Citicorp Venture Capital. However, the new Citicorp investments were not doing well. One particular failure, which Swanson later believed to have been a lucky break, was the bankruptcy of Antex, a science based company that Citicorp had invested in. He worked with Eugene Kleiner, another Citicorp executive, to attempt to get some money out of the company's bankruptcy. Eugene Kleiner was the cofounder of the venture capital partnership Kleiner & Perkins. Swanson left Citicorp and joined Kleiner & Perkins in 1974, under the recommendation of Eugene Kleiner himself. As an associate, Swanson spent a lot of time and effort attempting to convince the heads of the science company Cetus, one which Kleiner and Perkins had invested in, to pursue genetic recombination projects. His interest in the technology had been piqued in a lunch with famed scientist and Nobel laureate Donald Glaser. However, the company refused to take on such a risky endeavor, and Kleiner & Perkins parted ways with the company. This falling out was one of the main reasons for the group's decision to advise Swanson to look for another job. Kleiner & Perkins had decided that they would rather work alone, and by the end of 1975, Swanson's position there would be terminated.
Neuroimaging studies using resting state fMRI recently suggested that LSD changes the cortical functional architecture. These modifications spatially overlap with the distribution of serotonergic receptors. In particular, increased connectivity and activity were observed in regions with high expression of 5-HT2A receptor, while a decrease in activity and connectivity was observed in cortical areas that are dense with 5-HT1A receptor. Experimental data suggest that subcortical structures, particularly the thalamus, play a synergistic role with the cerebral cortex in mediating the psychedelic experience. LSD, through its binding to cortical 5-HT2A receptors, may enhance excitatory neurotransmission along frontostriatal projections and, consequently, reduce thalamic filtering of sensory stimuli towards the cortex. This phenomenon appears to involve ventral, intralaminar, and pulvinar nuclei selectively.
Due to the dynamic nature of O-GlcNAc and its presence on serine and threonine residues, O-GlcNAcylation is similar to protein phosphorylation in some respects. While there are roughly 500 kinases and 150 phosphatases that regulate protein phosphorylation in humans, there are only 2 enzymes that regulate the cycling of O-GlcNAc: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) catalyze the addition and removal of O-GlcNAc, respectively. OGT utilizes the sugar nucleotide UDP-GlcNAc as the donor sugar for transfer. First reported in 1984, this post-translational modification has since been identified on over 9,000 proteins in H. sapiens. Numerous functional roles for O-GlcNAcylation have been reported including crosstalking with serine/threonine phosphorylation, regulating protein-protein interactions, altering protein structure or enzyme activity, changing protein subcellular localization, and modulating protein stability and degradation. Numerous components of the cell's transcription machinery have been identified as being modified by O-GlcNAc, and many studies have reported links between O-GlcNAc, transcription, and epigenetics. Many other cellular processes are influenced by O-GlcNAc such as apoptosis, the cell cycle, and stress responses. As UDP-GlcNAc is the final product of the hexosamine biosynthetic pathway, which integrates amino acid, carbohydrate, fatty acid, and nucleotide metabolism, it has been suggested that O-GlcNAc acts as a "nutrient sensor" and responds to the cell's metabolic status.
== Side effects == Side effects experienced with this product will resemble those of other benzodiazepines. Drowsiness and asthenia are common side effects. There has been a report of reversible hepatitis caused by clotiazepam.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.